Bikin Fara Aikin Tushen Samarwa na Uku

The official commissioning of HONGAN’s third production base marks a significant new milestone in the company’s efforts to boost capacity, improve quality, and advance the inclusive healthcare ecosystem. We remain committed to driving innovation, applying efficient, intelligent production aligned with global quality standards to serve grassroots medical institutions, and striving hard to extend the benefits of technological progress to a wider population.

During this relocation, every member of the HONGAN team faced challenges head-on. They stood together in unity and supported one another throughout the process. In just half a month, we successfully completed the relocation of production workstations, facilities, equipment, supporting materials, and personnel. We also carried out a thorough site clean-up and rapidly completed the construction of a new plant built to high standards. The new plant spans approximately 1,500 square meters and houses several departments, including the Animal & Pet Division, Production Department, Warehousing Department, and After-sales Maintenance Department, to support our diversified development needs.

The building of HONGAN’s third production base is rooted in our corporate mission to “harness innovative technologies to alleviate the burden on healthcare and, by building an inclusive healthcare ecosystem, extend the benefits of technological progress to a wider population”. To date, HONGAN has delivered exceptional products and technical services to grassroots medical institutions across China with impressive outcomes.

We fully understand that mastery of core technologies and a robust supply chain form the bedrock for delivering safe, reliable products to the medical industry. With this new base, HONGAN will further refine the supply chain layout, reinforce autonomous control capabilities, drive product quality ever higher, and ultimately provide users with an even more outstanding healthcare experience!

In July 2024, HONGAN successfully obtained the CE conformity certificate in accordance with the EU In Vitro Diagnostic Medical Devices Regulation (Regulation (EU) 2017/746, commonly known as IVDR), followed by ISO 13485 certification in October 2024. These achievements once again demonstrate HONGAN’s robust capabilities in quality management and compliance with international standards.

The official commissioning of HONGAN’s third production base represents an important step in our pursuit of high-quality development and stands as a powerful testament to our unwavering commitment to “focusing on technologies for grassroots medical institutions and building China’s leading inclusive medical equipment”. Looking ahead, HONGAN will continue to drive industry transformation, guided by the corporate mission that “innovative technologies lead the testing revolution, intelligent applications empower testing at the grassroots”. We remain committed to exploring cutting-edge medical technologies to deliver safer, more precise healthcare solutions to users worldwide. Our relentless pursuit is to fulfill the inspiring vision of “extending the benefits of technological progress to a wider population”.